the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

Inclusion Criteria: * 18-75 years old,male and female * Mainly based on the criteria for liver cancer TNM stage I and II (edition 7) and BCLC stage A, the following needs to be satisfied: 1. individual tumor larger than or equal to 2 cm and smaller than or equal to 10 cm in the maximum diameter 2. multiple tumors with no more than three tumors 3. No macroscopic tumor embolus * ECOG performance state is 0-1 * Child-Pugh grade is A * The clinical review confirms the absence of recurrence within 8 weeks before the enrollment * Sign the informed consent Exclusion Criteria: * Pregnant and breast-feeding women * Patients with severe diseases in the brain, heart,lungs, kidneys and hematological system * Patients who have received other anti-tumor therapies before the surgery (including liver transplantation, TACE, local tumor ablation, chemotherapy, radiotherapy, molecular targeted therapy and other anti-tumor therapy) * DDS chemotherapy pump placed in the portal vein during the surgery * Patients who are participating in other drug trials * Patients known or suspected to be allergic to ginsenoside, with a history of allergy to biological preparations, allergic constitution or currently in an allergic state; * With active severe clinical infection * Epilepsy episode which needs drug therapy * With a history of allotransplantation; * With a previous history of tumor in other systems, but except for: 1. Carcinoma in situ of cervix 2. Basal cell carcinoma after treatment,Superficial bladder cancer (Ta, Tis and T1 3. Any cancer after curative treatment no less than three years ago * Patients with signs or a history of bleeding diathesis * Patients currently receiving kidney dialysis * A history of bleeding in the gastrointestinal tract within 30 days, or severe gastroesophageal varices with red signs; with a history of gastroesophageal variceal hemorrhage * Recurrent HCC * Patients unable to take drug orally * Patients inappropriate to participate in the trial upon the investigator's judgment